Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

sofosbuvir-velpatasvir drug combination MeSH Supplementary Concept Data 2025


MeSH Supplementary
sofosbuvir-velpatasvir drug combination
Unique ID
C000611331
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000611331
Entry Term(s)
Epclusa
sofosbuvir velpatasvir drug combination
sofosbuvir, velpatasvir drug combination
Pharm Action
Antiviral Agents
Registry Numbers
0
Heading Mapped to
*Carbamates
*Drug Combinations
*Heterocyclic Compounds, 4 or More Rings
*Sofosbuvir
Frequency
69
Note
A combined pharmaceutical preparation of the antiviral agents sofosbuvir and valpatasvir that is used to treat all six major genotypes of HEPATITIS C VIRUS (HCV) infections.
Source
Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8.
Date of Entry
2016/10/26
Revision Date
2020/11/23
sofosbuvir-velpatasvir drug combination Preferred
Epclusa Narrower
page delivered in 0.002s